Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  London Stock Exchange  >  GlaxoSmithKline    GSK   GB0009252882

Mes dernières consult.
Most popular
News SummaryMost relevantAll newsSector newsTweets

GlaxoSmithKline plc : GSK to acquire five million shares in Response Genetics for US$1.10 per share in cash

share with twitter share with LinkedIn share with facebook
share via e-mail
09/13/2012 | 02:29pm CET

This press release is intended for business journalists and analysts/investors. Please note that this release may not have been issued in every market in which GSK operates.

Issued: Thursday 13 September 2012, London, UK

GlaxoSmithKline plc (LSE: GSK) today announces that it has acquired five million newly issued shares of Response Genetics Inc. (RGI) (NASDAQ: RGDX) common stock at a purchase price of US$1.10 per share in cash. As a result, GSK now owns approximately 15.2% of the expanded share capital of RGI.

This transaction builds on the relationship GSK and RGI have been building over the years in the diagnostics field of oncology and vaccines. RGI performs companion diagnostic tests and other related activities for GSK's immunotherapies and oncology pipeline candidates.

GlaxoSmithKline - one of the world's leading research-based pharmaceutical and healthcare companies - is committed to improving the quality of human life by enabling people to do more, feel better and live longer.  For further information please visit www.gsk.com

GlaxoSmithKline Enquiries:

UK Media enquiries:

David Mawdsley

+44 (0) 20 8047 5502


Stephen Rea

+44 (0) 20 8047 5502


Sarah Spencer

+44 (0) 20 8047 5502


David Daley

+44 (0) 20 8047 5502


US Media enquiries:

Kevin Colgan

+1 919 483 2933

(North Carolina)

Melinda Stubbee

+1 919 483 2510

(North Carolina)

Sarah Alspach

+1 202 715 1048

(Washington, DC)

Jennifer Armstrong

+1 215 751 5664


Analyst/Investor enquiries:

Sally Ferguson

+44 (0) 20 8047 5543


Tom Curry

+ 1 215 751 5419


Gary Davies

+ 44 (0) 20 8047 5503


James Dodwell

+ 44 (0) 20 8047 2406


Jeff McLaughlin

+ 1 215 751 7002


Ziba Shamsi

+ 44 (0) 20 8047 3289


GlaxoSmithKline cautionary statement regarding forward-looking statements
Under the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, GSK cautions investors that any forward-looking statements or projections made by GSK, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Factors that may affect GSK' s operations are described under 'Risk factors' in the 'Financial review & risk' section in the company's Annual Report 2011 included as exhibit 15.2 to the company's Annual Report on Form 20-F for 2011.

distributed by
share with twitter share with LinkedIn share with facebook
share via e-mail
05:22p GLAXOSMITHKLINE : Data on Pre-Trial Research Detailed by Researchers at GlaxoSmi..
04:16p GLAXOSMITHKLINE : GSK achieves approval for Nucala for the treatment of eosinoph..
11:42aDJGLAXOSMITHKLINE : GSK Applies for Australian Approval of Malaria Treatment
11:17a GLAXOSMITHKLINE : GSK submits regulatory application for single-dose tafenoquine..
12/13 GLAXOSMITHKLINE : standalone profits reach LE102 m ending June
12/13 GLAXOSMITHKLINE : GSK presents promising new data for priority BCMA asset from i..
12/13 GLAXOSMITHKLINE : Upbeat On `Promising` Data From Dreamm-1 Blood Cancer Study
12/13 MIT's LEAPS pilot aims to integrate data generation
12/12 GLAXOSMITHKLINE : GSK achieves approval for Nucala (mepolizumab) for the treatme..
12/12 GLAXOSMITHKLINE : GSK gains US approval for Nucala to treat EGPA
More news
News from SeekingAlpha
08:06a GSK submits regulatory application for Tafenoquine for the treatment of Plasm..
12/13 GlaxoSmithKline (GSK) Oncology Investor & Analyst Update - Slideshow
12/13 YOUR DAILY PHARMA SCOOP : Omeros Potential, Portola's Setback, Proteostasis Soar..
12/12 FDA OKs expanded use for Glaxo's Nucala; shares up 1%
12/12 Glaxo's lead BCMA ADC candidate shows positive effect in early-stage study
Financials ( GBP)
Sales 2017 30 072 M
EBIT 2017 8 245 M
Net income 2017 3 652 M
Debt 2017 14 293 M
Yield 2017 6,09%
P/E ratio 2017 18,40
P/E ratio 2018 14,90
EV / Sales 2017 2,62x
EV / Sales 2018 2,58x
Capitalization 64 632 M
Duration : Period :
GlaxoSmithKline Technical Analysis Chart | GSK | GB0009252882 | 4-Traders
Technical analysis trends GLAXOSMITHKLINE
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus HOLD
Number of Analysts 32
Average target price 15,5  GBP
Spread / Average Target 18%
EPS Revisions
Emma Walmsley Chief Executive Officer & Executive Director
Philip Roy Hampton Non-Executive Chairman
Simon Dingemans Chief Financial Officer & Executive Director
Patrick J. T. Vallance Executive Director, President-R&D
Karenann K. Terrell Chief Technology Officer
Sector and Competitors
1st jan.Capitalization (M$)
JOHNSON & JOHNSON21.53%383 877
NOVARTIS12.01%221 304
PFIZER10.04%218 400
ROCHE HOLDING LTD.3.40%210 833
MERCK AND COMPANY-6.96%155 214